Faculty of pharmacy department of human pharmacology and toxicology

Ma J, Xiao L. (2010). Obesity and depression in US women: results from the 2005-2006 National Health and Nutritional Examination Survey. Obesity. Silver Spring, 18(2):347-53.

Manji, H., Kato, T., Di Prospero, N.A., et al., 2012. Impaired mitochondrial function in psychiatric disorders. Nat. Rev. Neurosci. 13 (5), 293–307

Mansur RB, Brietzke E, McIntyre RS. (2015). Is there a "metabolic-mood syndrome"? A review of the relationship between obesity and mood disorders. Neuroscience & Biobehavioral Reviews, 52:89-104.

Manthey L., Leedsa C., Giltay E.J., Veena T.V.,Vreeburg S.A.,Penninx B. W.J.H., Zitman F.G.(2011) Antidepressant use and salivary cortisol in depressive and anxiety disorders European Neuropsychopharmacology 21: 691–699

Markham, A., Cameron, I., Bains, R., et al., 2012. Brain-derived neurotrophic factor-mediated effects on mitochondrial respiratory coupling and neuroprotection share the same molecular signaling pathways. Eur. J. Neurosci. 35 (3),366–374.

Marosi, K., Mattson, M.P., 2014. BDNF mediates adaptive brain and body responses to energetic challenges. Trends Endocrinol. Metab. 25 (2), 89–98.

Matias, I., Gatta-Cherifi, B., Tabarin, A., et al., 2012. Endocannabinoids measurement in human saliva as potential biomarker of obesity. PLoS ONE 7 (7), e42399.

Maumus S, Marie B, Siest G, Visvikis-Siest S. (2005). A prospective study on the prevalence of metabolic syndrome among healthy french families: two cardiovascular risk factors (HDL cholesterol and tumor necrosis factor-alpha) are revealed in the offspring of parents with metabolic syndrome. Diabetes Care, 28:675–82.

McIntyre RS, Konarski JZ, Wilkins K, Soczynska JK, Kennedy SH. (2006). Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Canadian Journal of Psychiatry, 51(5):274-80.

McIntyre RS, Konarski JZ, Wilkins K, Soczynska JK, Kennedy SH. (2006). Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Canadian Journal of Psychiatry, 51(5):274-80.

McIntyre RS, Park KY, Law CW, Sultan F, Adams A, Lourenco MT, et al. (2010). The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications. CNS Drugs, 24:741–53.

McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. (2012). Lithium toxicity profile: a systematic review and meta-analysis. Lancet, 379(9817):721-728.

McMurray RG, Zaldivar F, Galassetti P, Larson J, Eliakim A, Nemet D, Cooper DM. (2007). Cellular immunity and inflammatory mediator responses to intense exercise in overweight children and adolescents. Journal of Investigation Medicine, 55(3):120-9.

Meyer JM (2001). Effects of typical Antipsychotics on weight and serum lipid levels. Journal of Clinical Psychiatry, 62(27):27–34.

Michelson D, Amsterdam JD, Quitkin FM, Reimherr FW, Rosenbaum JF, Zajecka J, et al. Changes in weight during 1- year trial of fluoxetine. Am J Psychiatry. 1999;156:1770–6.

Midei, A.J., Matthews, K.A., Bromberger, J.T. (2010). Childhood abuse is associated with adiposity in midlife women: possible pathways through trait anger and reproductive hormones. Psychosomal Medicine, 72(2):215–223.

Midei, A.J., Matthews, K.A., Chang, Y.F., Bromberger, J.T. (2013). Childhood physical abuse is associated with incident metabolic syndrome in mid-life women. Health Psychol. 32 (2), 121–127.

Milaneschi, Y., Simonsick, E.M., Vogelzangs, N., et al. (2012). Leptin, abdominal obesity, and onset of depression in older men and women. Journal of Clinical Psychiatry, 73 (9):1205–1211.

Minet Kinge J, Morris S. (2009). Socioeconomic variation in the impact of obesity on health-related quality of life. Social Science Medicine, 21:21.

Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. (2013), Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders – a systematic review and meta-analysis. Schizophrenia Bulletin, 39:306–18.

Mitchell, A.J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W., de Hert, M. (2013). Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders - A systematic review and meta-analysis. Schizophrenia Bulletin, 39:306–318.

MoorE ME, Stunkard A, Srole L. (1962). Obesity, social class, and mental illness. JAMA,181(15):962-6.

Moreira, F.A., Kaiser, N., Monory, K., Lutz, B., 2008. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1receptors. Neuropharmacology 54 (1), 141–150.

Morris DL., Rui L. (2009). Recent advances in understanding leptin signaling and leptin resistance. American Journal of Physiology Endocrinol Metabism, 297(6): E1247‐59.

Muench J, Hamer AM. (2010). Adverse effects of antipsychotic medications. American Family of Physician, 81(5):617-622.

Mujica-Parodi, L.R., Renelique, R., Taylor, M.K. (2009). Higher body fat percent-age is associated with increased cortisol reactivity and impaired cognitive resilience in response to acute emotional stress. International Journal of Obesity, 33(1):157–165.

Munkholm, K., Vinberg, M., Vedel Kessing, L. (2013). Cytokines in bipolar disorder: a systematic review and meta-analysis. Journal Affective Disorders, 144(1–2):16–27.

Munzberg H. (2010). Leptin-signaling pathways and leptin resistance, Forum of Nutrition, 63:123–132.

Munzberg H., Myers MG Jr. (2005). Molecular and anatomical determinants of central leptin resistance,” Nature Neuroscience, 8(5):566–570.

Murashita M, Inoue T, Kusumi I et al. (2007). Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. Psychiatry Clin Neuroscience, 61:54-58.

Myint AM, Schwarz MJ, Muller N. The role of the kynurenine metabolism in major depression. J Neural Transm 2012;119(2):245–51.

Nanni, V., Uher, R., Danese, A. (2012). Childhood maltreatment predicts the unfavorable course of illness and treatment outcome in depression: a meta-analysis. American Journal of Psychiatry, 169(2):141–151.

Nasrallah HA (2008). Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Molecular Psychiatry, 13:27-35.

Newcomer J. (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review? CNS Drugs, 19.

O'Brien SM, Scully P, Fitzgerald P, Scott LV, Dinan TG. (2007). Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. Journal of Psychiatric Research, 41(3-4):326-31.

Oken, E., Gillman, M.W. (2003). Fetal origins of obesity. Obesity Research 11:496–506.

Onyike CU, Crum RM, Lee HB, Lyketsos CG, Eaton WW. (2003) Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey. American Journal of Epidemiology, 158:1139–1147.

Onyike CU, Crum RM, Lee HB, Lyketsos DG, Eaton WW. (2003). Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey. American Journal of Epidemiology, 158(12):1139–47. 2003.

Oxenkrug G.F. Metabolic syndrome, age-associated neuroendocrine disorders, and dysregulation of tryptophan—kynurenine metabolism. 2010 Annals of the New York academy of science. 1199:1-14.

Panariello F., De Luca V., Bartolomeis A.(2011) Weight Gain, Schizophrenia and Antipsychotics: New Findings from AnimalModel and Pharmacogenomic Studies. Schizophrenia Research and Treatment .1155:1-16

Pande AC, Birkett M, Fechner-Bates S, Haskett RF, Greden JF.(1996) Fluoxetine versus phenelzine in atypical depression. Biol Psychiatry. 40:1017–20.

Paredes S., Ribeiro L. (2014). Cortisol: the villain in Metabolic Syndrome? Rev. Assoc. Med. Bras. 60(1).

Parsons B, et al. (2009). Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophrenia Research, 110:103–10.

Pasquali R, Vicennati V, Cacciari M, Pagotto U. (2006). The hypothalamic-pituitary-adrenal axis activity in obesity and the metabolic syndrome. Ann N Y Acad Science, 1083:111-28.

Pasquali, R. (2012). The hypothalamic–pituitary–adrenal axis and sex hormones in chronic stress and obesity: pathophysiological and clinical aspects. Annual N. Y. Academic Science, 1264:20–35.

Patten S, B, Williams J, V, A, Lavorato D, H, Brown L, McLaren L, Eliasziw M. (2009). Major Depression, Antidepressant Medication and the Risk of Obesity. Psychotherapy Psychosom, 78:182-186

Patten SB, Beck CA, Kassam A, Williams JV, Barbui C, Metz LM. (2005). Long-term medical conditions and major depression: strength of association for specific conditions in the general population. Canadian Journal of Psychiatry, 50:195-202.

Patten SB, Williams JV, Lavorato DH, Khaled S, Bulloch AG.Weight gain in relation to major depression and antidepressant medication use. J Affect Disord 2011;134:288–93.

Pearson, R.M., Evans, J., Kounali, D., et al., 2013. Maternal depression during preg-nancy and the postnatal period: risks and possible mechanisms for offspring depression at age 18 years. JAMA Psychiatry, 70(12):1312–1319.

Pervanidou, P., Chrousos, G.P. (2012). Metabolic consequences of stress during child-hood and adolescence. Metabolism,61(5):611–619.

Petry NM, Barry D, Pietrzak RH, Wagner JA. (2008). Overweight and obesity are associated with psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosom Medicine, 70(3):288-97.

Plotsky PM, Owens MJ, Nemeroff CB. (1998). Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. Psychiatry Clinic North America, 21:293−307.

Potvin S, Zhornitsky S, Stip E. (2015). Antipsychotic-Induced Changes in Blood Levels of Leptin in Schizophrenia: A Meta-Analysis. CanJPsychiatry 60 (2):26-34

Poulose BK, Holzman MD, Zhu Y, Smalley W, Richards WO, Wright JK, Melvin W, Griffin MR. (2005). National variations in morbid obesity and bariatric surgery use. Journal of the American College of Surgeons, 201(1):77-84.

Poyurovsky, M., Isaacs, I., Fuchs, C., Schneidman, M., Faragian, S., Weizman, R., et al. (2003). Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry 160, 297−302.

Pratt L.A., Brody D.J. (2014). Depression and Obesity in the U.S. Adult Household Population, 2005–2010. NCHS Data Brief, 167.

Proietto J. Diabetes and Antipsychotic Drugs. Prescriber Update 2004;25(2):20-22.

Pylvanen V., Pakarinen A., Knip M., Isojarvi J. 2006 Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy & Behavior 8:643–648.

Qiao L, Schaack J, Shao J. Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid. Endocrinology. 2006;147:865–74.

Raeder MB, Ferno J, Vik-Mo AO, Steen VM. (2006) SREBP activation by antipsychotic- and antidepressant drugs in cultured human liver cells: relevance for metabolic side-effects? Mol Cell Biochem. 289:167–73.

Raisanen, S., Lehto, S.M., Nielsen, H.S., Gissler, M., Kramer, M.R., Heinonen, S. (2014). Risk factors for and perinatal outcomes of major depression during pregnancy: a population-based analysis during 2002–2010 in Finland. BMJ, 4(11):e004883.

Ramasubbu R. (2002). Insulin resistance: A metabolic link between depressive disorder and atherosclerotic vascular diseases. Medicine Hypotheses, 59:537-551.

Reeves, G.M., Postolache, T.T., Snitker, S. (2008). Childhood Obesity and Depression: Connection between these Growing Problems in Growing Children. International Journal of Child Health and Human Development : IJCHD, 1(2):103–114.

Reynolds G, Kirk S.2010 Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms. Pharmacology & Therapeutics, 125:169-179.

Rivera M, Cohen-Woods S, Kapur K, Breen G, Ng MY, Butler AW et al. (2012). Depressive disorder moderates the effect of the FTO gene on body mass index. Molecular Psychiatry, 17(6):604-11.

Ruetsch O , Viala A , Bardou H , Martin P , Vacheron MN., (2005). Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management. L'Encéphale 31 (4): 507–516.

Russo, S.J., Nestler, E.J., 2013. The brain reward circuitry in mood disorders. Nat. Rev.Neurosci. 14 (9), 609–625.

Ruttle, P.L., Klein, M.H., Slattery, M.J., Kalin, N.H., Armstrong, J.M., Essex, M.J., (2014). Adolescent adrenocortical activity and adiposity: differences by sex and expo-sure to early maternal depression. Psychoneuroendocrinology, 4:68–77.

Ryan MC, Collins P, Thakore JH. (2003). Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. American Journal of Psychiatry, 160:284–289.

Saddichha S, Manjunatha N, Ameen S, Akhtar S. Metabolic syndrome in first episode schizophrenia—a randomized double-blind controlled, short-term prospective study. Schizophr Res. 2008;101:266–72

Salvi V., Barone-Adesi F., D’Ambrosio V., Albert U., Maina G., (2016). High H1-affinity antidepressants and risk of metabolic syndrome in bipolar disorder . Psychopharmacology, 233:49-56

Sanhueza, C., Ryan, L., Foxcroft, D.R. (2013). Diet and the risk of unipolar depression in adults: systematic review of cohort studies. Journal of Human Nutrition Diet, 26(1):56–70.

Santini I, Stratta P, D’onofrio S, DE Lauretis I, Santarelli V, Pacitii F, Rossi A 2016. The metabolic syndrome in an Italian psychiatric sample: a retrospective chart review of inpatients treated with antipsychotics. Riv Psichiatr; 51(1): 37-42

Saravane D. (2012). Dyslipidemia and Mental Illness. In Kelishadi R (ed). Dyslipidemia - From Prevention to Treatment. US: InTech. Online, retrieved from http://cdn.intechweb.org/pdfs/27505.pdf

Sassi, F., Devaux, M., Church, J. (2009). Education and Obesity in Four OECD Countries. OECD Health Working Paper No. 46. OECD Publishing, Paris.

Scherer P.E. (2006). Adipose Tissue: From Lipid Storage Compartment to Endocrine Organ. Diabetes 55:1537-1545.

Schilling C, Gilles M, Blum WF et al (2013) Leptin plasma concentration increase during antidepressant treatment with amitriptyline and mirtazapine, but not paroxetine and venlafaxine: leptin resistance mediated by antihistaminergic activity? J Clin Psychopharmacol 33:99–10.

Scott KM, McGee MA, Wells JE, Oakley-Browne MA. (2008) . Obesity and mental disorders in the adult general population . Journal of Psychosom Res, 64:97-105.

Scott KM, McGee MA, Wells JE, Oakley-Browne MA. (2008). Obesity and mental disorders in the adult general population. Journal of Psychosom Research, 64:97-105.

Scuteri A, Sanna S, Chen WM, Uda M, Albai G, Strait J, et al. (2007). Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet ; 3:e115.

Sechter D, Peuskens J, Fleurot O, Rein W, Lecrubier Y, Amisulpride Study Group. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology. 2002;27(6):1071–81.

Serretti A, Mandelli L. (2010). Antidepressants and bodyweight: a comprehensive review and meta-analysis. Journal of Clinical Psychiatry, 71:1259–72.

Shibli-Rahhal A , Schlechte J. 2009 The effects of hyperprolactinemia on bone and fat. Pituitary 12(2):96-104.

Shugart, Y.Y., Chen, L., Day, I.N., et al., 2009. Two British women studies replicated the association between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) and BMI. Eur. J. Hum. Genet. 17 (8), 1050–1055.

Silvestre JS, Prous J. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol. 2005;27(5):289–304.

Simon GE, Von Korff M, Saunders K, Miglioretti DL, Crane PK, van Belle G, Kessler RC. (2006). Association between obesity and psychiatric disorders in the US adult population. Archive of Genetic Psychiatry, 63(7):824-30.

Smoller, J.W., Finn, C.T. (2003). Family, twin, and adoption studies of bipolar disorder. American Journal of Medicine and Genetics, 123C(1):48–58.

Speakman JR. (2004). Obesity: the integrated roles of environment and genetics. Journal of Nutrition, 13(8):090‐210S.

Spelman, L.M., Walsh, P.I., Sharifi, N., Collins, P., Thakore, J.H. (2007). Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabetic Medicine, 24:481–485.

Stetler, C., Miller, G.E. (2011). Depression and hypothalamic–pituitary–adrenal activation: a quantitative summary of four decades of research. Psychosomal Medicine, 73(2):114–126.

Strakowski, S.M., Adler, C.M., Almeida, J. et al. (2012). The functional neuroanatomy of bipolar disorder: a consensus model. Bipolar Disorder, 14(4):313–325.

Stubbs B., Wanfg K.A., Vancamproft D., Miller B.J. (2016). Are leptin levels increased among people with schizophrenia versus controls? A systematic review and comparative meta-analysis. Psychoneuroendocrinology, 63:144–154.

Stunkard AJ, Faith MS, Allison KC. (2003). Depression and Obesity. 54(3):330–337.

Taylor V, Macdonald K, McKinnon MC, Joffe RT, MacQueen GM. (2008). Increased rates of obesity in first-presentation adults with mood disorders over the course of four-year follow-up. Journal of Affective Disorder, 109(1-2):127-31.

Teff K,L, Kim S,F. 2011. Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism. Physiology & Behavior , 104: 590–598

Teh, A.L., Pan, H., Chen, L., et al. (2014). The effect of genotype and in utero environment on interindividual variation in neonate DNA methylomes. Genome Research, 24(7):1064–1074.

Teixeira PJ, Rocha FL. (2007). The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Review of Bras Psychiatry, 29:330–6.

Teixeira PJR , Rocha FL. Metabolic side effects of antipsychotics and mood stabilizers. Review Article.2006.h.1-22.

Terevnikov V, Stenberg J.H, Tiihonen J, Chukhin E, Joffe M, Burkin M, Joffe G. Relationships between pharmacotherapy-inducedmetabolic changes and improved psychopathologyin schizophrenia: data from a mirtazapine andfirst-generation antipsychotics combination trial. International Journal of Neuropsychopharmacology , 2013 16: 1661–1666

Thrush, A.B., Dent, R., McPherson, R., Harper, M.E., 2013. Implications of mitochondrial uncoupling in skeletal muscle in the development and treatment of obesity.FEBS J. 280 (20), 5015–5029.

Tiller JW, Biddle N, Maguire KP, Davies BM.(1988). The dexamethasone suppression test and plasma dexamethasone in generalized anxiety disorder. Biological Psychiatry, 23:261−270

Torrent C, Amann B, Sánchez-Moreno J, et al. (2008). Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatry Scand, 118(1):4-18.

Uguz F, Sahingoz M, Gungor B, Aksoy F, Askin R. (2015). Weight gain and associated factors in patients using newer antidepressant drugs. General Hospital of Psychiatry, 37(1):46-8.

Ujike H, Nomura A, Morita Y, Morio A, Okahisa Y, Kotaka T, et al. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J Clin Psychiatry. 2008;69:1416-22.

Unger, T.J., Calderon, G.A., Bradley, L.C., Sena-Esteves, M., Rios, M., 2007. Selective deletion of Bdnf in the ventromedial and dorsomedial hypothalamus of adult mice results in hyperphagic behavior and obesity. J. Neurosci. 27 (52),14265–14274.

van de Giessen, E., Celik, F., Schweitzer, D.H., van den Brink, W., Booij, J., 2014.Dopamine D2/3 receptor availability and amphetamine-induced dopamine release in obesity. J. Psychopharmacol. 28 (9), 866–87

van der Merwe MT. (2007). Psychological correlates of obesity in women. International Journal of Obesity, 31(2): S14-8.

Vancampfort, D., Correll, C.U., Probst, M., et al. (2013). A review of physical activity correlates in patients with bipolar disorder. Journal of Affective Disorder,145(3):285–291.

Vanina Y, Podolskaya A, Sedky K, Shahab H, Siddiqui A, Munshi F, et al. (2002) Body weight changes associated with psychopharmacology. Psychiatr Serv, 53:842–7

Vargas, C., Lopez-Jaramillo, C., Vieta, E. (2013). A systematic literature review of resting-state network-functional MRI in bipolar disorder. Journal of Affective Disorders, 150(3):727–735.

Vederine, F.E., Wessa, M., Leboyer, M., Houenou, J. (2011). A meta-analysis whole-brain diffusion tensor imaging studies in bipolar disorder. Prog. Neuropsychopharmacol. Biology Psychiatry, 35(8):1820–1826.

Verrotti A, D'Egidio C, Mohn A, Coppola G, Chiarelli F.. (2011). Weight gain following treatment with valproic acid: pathogenic mechanisms and clinical implications. Obesity Review, 12(5):e-32-43.

Versiani M, Moreno R, Ramakers-van Moorsel CJ, Schutte AJ. Comparative efficacy antidepressants study group. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs. 2005;19:137–46.

Vicennati V, Pasqui F, Cavazza C, Pagotto U, Pasquali R. (2009). Stress-related development of obesity and cortisol in women. Obesity, 17:1678-83.

Volpato A, Zugno A, Quevedo J. Recent evidence and potential mechanisms underlying weight gain and insulin resistance due to atypical antipsychotics. 2013 Laboratory of Neurosciences, 35:295–304

Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R. Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2011;12:CD006528.

Watson, S., Gallagher, P., Dougall, D., et al (2013). Childhood trauma in bipolar disorder. Aust. N. Z. J. Psychiatry.

Weissman MM, Bland R, Joyce PR, Newman S, Wells JE, Wittchen HU. (1993). Sex differences in rates of depression: cross-national perspectives. Journal of Affective Disorders, 29(2-3):77-84.

Wirshing D. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry. 2004;65 Suppl 18:13-26.

White W., Elmore L., Luthin D., Cates M. (2013). Psychotropic-Induced Weight Gain: A Review of Management Strategies. Consultant, 53(3).

Wilson PW, D’ Agostoni RB, Sullivan L, Parise H, Kanne; WB. (2002). Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Archive of International Medicine, 162:1867-72.

Winham S.J., Biernacka J.M. (2013). Gene–environment interactions in genome-wide association studies: current approaches and new directions. Journal of Child Psychology Psychiatry, 54(10), 1120–1134.

Wirshing D. (2004). Schizophrenia and obesity: impact of antipsychotic medications. Journal of Clinical Psychiatry, 65 Suppl 18:13-26.

Wise TN, Perahia DG, Pangallo BA, LosinWG, Wiltse CG. Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies. Prim Care Companion. Journal Clinical Psychiatry, 8:269–78.

Wojcik, W., Lee, W., Colman, I., Hardy, R., Hotopf, M. (2013). Foetal origins of depression? A systematic review and meta-analysis of low birth weight and later depression. Psychology Medicine, 43(1):1–12.

Wong, M.L., Kling, M.A., Munson, P.J., et al. (2000). Pronounced and sustained central hyperadrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc. Natl.Acad. Sci. U. S. A., 97(1):325–330.

Wu, C.S., Nohr, E.A., Bech, B.H., Vestergaard, M., Olsen, J. (2012). Long-term healthy outcomes in children born to mothers with diabetes: a population-based cohort study. PLoS ONE, 7(5):e36727.

Wu, X., Huang, Z., Wu, R., Zhong, Z., Wei, Q., Wang, H., Diao, F., Wang, J., Zheng, L., Zhao, J., Zhang, J. (2013). The comparison of glycometabolism parameters and lipid profiles between drug-naive, first-episode schizophrenia patients and healthy controls. Schizophrenia Research, 150:157–162.

Wurtman RJ, Wurtman JJ. (1995). Brain serotonin, carbohydrate-craving, obesity, and depression. Obesity Research, 3(4):477S-480S.

Wysokinski A, Kowman M, Knoszewska I. (2012). The prevalence of metabolic syndrome and Framingham cardiovascular risk scores in adult inpatients taking antipsychotics - a retrospective medical records review. Psychiatry Danub, 24:314-322.

Wysokiński A, Strzelecki D, Kłoszewska I. (2015). Levels of triglycerides, cholesterol, LDL, HDL and glucose in patients with schizophrenia, unipolar depression, and bipolar disorder. Diabetes Metab Syndrome, 9(3):168-76.

Wysokinski A., Knoszewska I. (2014). Mechanisms of Increased Appetite and Weight Gain Induced by Psychotropic Medications. Journal of Advanced Clinical Pharmacology, 1:12-33.

Xu Q, Anderson D, Lurie-Beck J. (2011). The relationship between abdominal obesity and depression in the general population: a systematic review and meta-analysis. Obes Res Clin Practice, 5:e267–e360.

Young EA, Haskett RF, Grunhaus L, Pande A, Weinberg VM et al. (1994). Increased evening activation of the hypothalamic-pituitary-adrenal axis in depressed patients. Archive Gen Psychiatry, 51:701−707.

Yumru M, Savas HA, Kurt E, Kaya MC, Selek S, Savas E, et al. (2007). Atypical antipsychotics related metabolic syndrome in bipolar patients. Journal of Affective Disorder, 98:247–52.

Zagrebelsky, M., Korte, M., 2014. Form follows function: BDNF and its involvement in sculpting the function and structure of synapses. Neuropharmacology 76 (PtC), 628–638.

Zai CC, Tiwari AK, Chowdhury NI, Brandl EJ, Shaikh SA, Freeman N. Association study of GABAA alpha2 receptor subunit gene variants in antipsychotic-associated weight gain. J Clin Psychopharmacol. 2015;35:7–12.

Zhang, X. Y., Zhou, D. F.,Wu, G. Y., Cao, L. Y., Tan, Y. L.,Haile, C. N., et al. (2008). BDNF levels and genotype are associated with antipsychotic-induced weight gain in patientswith chronic schizophrenia. Neuropsychopharmacology 33(9), 2200−2205

Zhang XY, Chen DC, Tan YL, An HM, Zunta-Soares GB, Huang XF, Soares JC. (2015). Glucose disturbances in first-episode drug-naïve schizophrenia: Relationship to psychopathology. Psychoneuroendocrinology, 62:376-80.

Zhao G, Ford ES, Dhingra S, Li C, Strine TW, Mokdad AH. (2009). Depression and anxiety among US adults: Associations with body mass index. Intl Journal of Obesity, 33(2):257–66. 2009.

Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollmacher T. (2003). Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. Journal of Psychiatric Research, 37:193-220.

.